Literature DB >> 18752439

Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation.

Rafael San Juan1, José Maria Aguado, Carlos Lumbreras, Jesus Fortun, Patricia Muñoz, Joan Gavalda, Francisco Lopez-Medrano, Miguel Montejo, German Bou, Marino Blanes, Antonio Ramos, Asuncion Moreno, Julian Torre-Cisneros, Jorge Carratalá.   

Abstract

BACKGROUND: Current advances in transplantation practices may influence the development of cytomegalovirus (CMV) disease after renal transplantation.
METHODS: From September 2003 through February 2005, 1470 renal transplant recipients (55 of whom were kidney-pancreas transplant recipients) were prospectively studied in the 16 transplant centers affiliated with the Spanish Network of Infection in Transplantation, with use of an ad hoc-designed online database. Univariate and multivariate analyses with logistic regression were performed to detect risk factors for CMV disease.
RESULTS: A total of 105 episodes of CMV disease (37 with visceral involvement) developed in 99 (6.7%) of 1470 patients. Attributable mortality appeared in 1 (1.0%) of 105 cases. Multivariate analysis showed that, apart from CMV serological mismatch, presence of rejection episodes, and the use of antilymphocitic drugs, a simultaneous pancreas transplantation (odds ratio [OR], 3.7; 95% confidence interval [CI], 1.5-9), use of cyclosporine (OR, 1.7; 95% CI, 1.18-2.9), a donor >60 years of age (OR, 2.3; 95% CI, 1.5-3.7), and chronic graft malfunction (OR, 1.8; 95% CI, 1.14-2.9) were independently associated with CMV disease, whereas use of sirolimus had a protective effect (OR, 0.27; 95% CI, 0.1-0.78).
CONCLUSIONS: Additional risk factors related to current transplantation practices influence the epidemiology of CMV after renal transplantation and should be taken into account in the design of prophylactic strategies in this population of kidney or kidney-pancreas recipients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752439     DOI: 10.1086/591532

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

Review 1.  Management of cytomegalovirus infection in solid organ transplantation.

Authors:  Camille N Kotton
Journal:  Nat Rev Nephrol       Date:  2010-10-26       Impact factor: 28.314

Review 2.  Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity.

Authors:  M L Ritter; L Pirofski
Journal:  Transpl Infect Dis       Date:  2009-05-26       Impact factor: 2.228

Review 3.  Immunosuppression and allograft rejection following lung transplantation: evidence to date.

Authors:  Gregory I Snell; Glen P Westall; Miranda A Paraskeva
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 4.  New developments in the management of cytomegalovirus infection after solid organ transplantation.

Authors:  Albert J Eid; Raymund R Razonable
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

5.  Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.

Authors:  F L Luan; M Samaniego; M Kommareddi; J M Park; A O Ojo
Journal:  Transpl Infect Dis       Date:  2010-12       Impact factor: 2.228

6.  Frequncy and etiology of lymphadenopathy in Iranian HIV/AIDS patients.

Authors:  Azar Hadadi; Sirous Jafari; Zahra Hoseini Jebeli; Reza Hamidian
Journal:  Asian Pac J Trop Biomed       Date:  2014-05

7.  Clinical Experience with Immune Monitoring for Cytomegalovirus in Solid-Organ Transplant Recipients.

Authors:  Oriol Manuel
Journal:  Curr Infect Dis Rep       Date:  2013-09-29       Impact factor: 3.725

Review 8.  Antiviral drug resistance: mechanisms and clinical implications.

Authors:  Lynne Strasfeld; Sunwen Chou
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982

9.  Cytomegalovirus disease in African-American kidney transplant patients.

Authors:  J McGee; V Mave; C L Yau; M Killackey; A Paramesh; J Buell; D P Slakey; L L Hamm; R Zhang
Journal:  Transpl Infect Dis       Date:  2012-12       Impact factor: 2.228

10.  Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection.

Authors:  Fu L Luan; Linda J Stuckey; Jeong M Park; Daniel Kaul; Diane Cibrik; Akinlolu Ojo
Journal:  J Am Soc Nephrol       Date:  2009-09-17       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.